Home

Unlearn Appoints Its First Vice President of Product

via Business Wire

Kwame Marfo brings more than 15 years of experience at the intersection of life sciences, health technology, and product innovation

Unlearn®, a leader in AI solutions for clinical trials, today announced the appointment of Kwame Marfo as its Vice President of Product. Marfo’s appointment solidified Unlearn’s trajectory, as it continues to scale and advance its digital twin technology to improve the speed and efficiency of clinical research. In his role, Marfo will spearhead product strategy and development, ensuring Unlearn’s offerings remain tightly aligned with the evolving needs of pharmaceutical partners and global regulatory bodies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250729913939/en/

“Kwame brings the rare combination of deep domain expertise and a sharp product mindset that will be invaluable as we continue to scale,” said Steve Herne, CEO of Unlearn. “His experience improving trial design and execution aligns closely with our mission to accelerate research through digital twin technology and will further position Unlearn as a market leader reshaping clinical trial design and execution.”

Marfo joins Unlearn from Komodo Health, where he served as Senior Director of Product Strategy and Incubation. There, he led cross-functional teams to advance product development and drive market alignment across multiple healthcare segments, including clinical development and medical affairs. Prior to Komodo, Marfo spent more than a decade at Genentech in leadership roles across global clinical operations and manufacturing sciences and technology. As Director of Insights & Analytics for Genentech’s Global Clinical Operations, he co-founded a function that became central to trial strategy and execution, with a strong focus on improving trial representation, patient experience, and accelerating timelines. He holds a BS in Chemical Engineering from Stanford University and an MBA from the Haas School of Business at UC Berkeley.

“Unlearn is tackling one of the most longstanding challenges in healthcare by modernizing clinical trials and helping bring effective treatments to patients faster,” said Marfo. “I’m excited to join a team that’s not only leading in AI innovation, but also rethinking legacy systems with a deep commitment to scientific rigor and real-world patient impact.”

For more information about Unlearn, visit: www.unlearn.ai

About Unlearn

Unlearn (www.unlearn.ai) partners with pharma and biotech companies to design and optimize clinical trials using AI-powered digital twins. By forecasting patients’ clinical outcomes, Unlearn helps sponsors refine trial design, shorten timelines, and increase the chance of detecting treatment effects in less time. With a science-first approach and deep regulatory engagement—including EMA qualification and FDA endorsement—Unlearn is transforming clinical development to be faster, smarter, and more reliable.

For more information, visit www.unlearn.ai or follow us on LinkedIn and X/Twitter.

Contacts